Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Fate Therapeutics
- Registration Number
- NCT05934097
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2400
- Registration Number
- NCT05929768
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT05922930
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CAR T-cell Therapy in Patients With Renal Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05909059
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT05909826
The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Target Recruit Count
- 260
- Registration Number
- NCT05907486
Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT05907746
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1736
- Registration Number
- NCT05901428
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Delayed Tolerance Through Mixed Chimerism
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05900401
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.